Vir Biotechnology与Gilead达成PRO-XTEN双掩蔽T细胞衔接器多项目合作：近期付款最高1.35亿美元、里程碑总额最高17.4亿美元，但消息签署日已反应、公告日盘前冲高约18%后倒跌

Vir Biotechnology, Inc. (VIR) has entered into a multi-program collaboration and license agreement with Gilead Sciences (GILD) to discover and develop three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Under the agreement, Gilead will receive exclusive rights to develop and commercialize the resulting therapies.
T-cell engagers are designed to direct the body's immune system to recognize and attack cancer cells. Vir's PRO-XTEN technology is intended to keep these therapies inactive until they reach the tumor microenvironment, potentially reducing unwanted side effects while improving their ability to target cancer cells.
As part of the partnership, Vir will use its T-cell engager discovery capabilities, AI-powered dAIsy protein engineering platform and PRO-XTEN masking technology to identify and optimize the three candidates. Gilead will then be responsible for further development, manufacturing and commercialization.
The deal could provide Vir with up to $135 million in upfront and near-term preclinical milestone payments, including $65 million in cash, a $25 million equity investment from Gilead at a 30% premium, and up to $45 million in additional near-term milestones. Vir is also eligible to receive up to $1.74 billion in future development, regulatory and commercial milestone payments, along with tiered royalties on potential product sales.
The collaboration is Vir's second partnership centered on its PRO-XTEN platform and reflects growing industry interest in technologies designed to improve the safety and effectiveness of T-cell engager therapies for solid tumors.
For Gilead, the agreement expands its oncology pipeline with access to new immunotherapy candidates, while Vir gains additional funding and an opportunity to advance its technology through a major pharmaceutical partner.
VIR has traded between $4.82 and $12.00 over the past year. The stock is currently trading at $10.55, down 0.75%
GILD has traded between $114.02 and $157.29 over the past year. The stock is currently trading at $151.15, up 2.18%
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.